Myriad Genetics shares underperformed the market index on August 6, 2025, while operating in the biomedical and genetics industry and tracking earnings estimate revisions.
2 reports, 1 independent
Updated Aug 6
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Myriad Genetics shares underperformed the market index on August 6, 2025, while operating in the biomedical and genetics industry and tracking earnings estimate revisions.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Coverage
Newest first; wire copies grouped- ZacksMyriad Genetics (MYGN) Q2 Earnings and Revenues Surpass Estimates Myriad Genetics (MYGN) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.01 p
- ZacksCompared to Estimates, Myriad (MYGN) Q2 Earnings: A Look at Key Metrics Myriad Genetics (MYGN) reported $213.1 million in revenue for the quarter ended June 2025, representing a year-over-year increa